CIK 0001869105 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
BridgeBio Oncology Therapeutics, Inc.
Sign in to watch- Ticker
- BBOT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 857 702 0377
- Business address
- 256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Helix Acquisition Corp. II
- 3 Insider Initial Statement of Ownership
- POS AM Other Post-effective Amendment for Registration Statement
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 4 Grant or award Director acquired 10,950,408 shares (grant or award)
- 8-K Event Material agreement · Acquisition or sale completed · Unregistered share sale · Shareholder rights changed · Auditor change · Change in control · Executive or director change · Bylaws or fiscal year change · Code of ethics change · Shell status change · Regulation FD disclosure · Other events
- 3 Insider Initial Statement of Ownership
- 4 Insider Changes in Ownership
- 4 Insider Changes in Ownership
- 4 Option exercise Former Director acquired 30,000 shares (option exercise)
- 4 Option exercise Former Director acquired 30,000 shares (option exercise)
- 4 Option exercise Former Director acquired 30,000 shares (option exercise)
- 8-K Event Regulation FD disclosure
- 425 Deal Prospectus/Communication re Business Combination
- 8-K Event Shareholder vote results
- 10-Q Report Quarterly Report
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 424B3 Offering Prospectus
- 425 Deal Prospectus/Communication re Business Combination
- 425 Deal Prospectus/Communication re Business Combination
Page 6 of 10 · 187 filings